| Literature DB >> 24976853 |
Mônica Santos de Melo1, Jullyana de Souza Siqueira Quintans1, Adriano Antunes de Souza Araújo2, Marcelo Cavalcante Duarte2, Leonardo Rigoldi Bonjardim3, Paulo Cesar de Lima Nogueira4, Valéria Regina de Souza Moraes4, João Xavier de Araújo-Júnior5, Eurica Adélia Nogueira Ribeiro5, Lucindo José Quintans-Júnior6.
Abstract
Background. Clusiaceae family (sensu lato) is extensively used in ethnomedicine for treating a number of disease conditions which include cancer, inflammation, and infection. The aim of this review is to report the pharmacological potential of plants of Clusiaceae family with the anti-inflammatory activity in animal experiments. Methods. A systematic review about experiments investigating anti-inflammatory activity of Clusiaceae family was carried out by searching bibliographic databases such as Medline, Scopus and Embase. In this update, the search terms were "anti-inflammatory agents," "Clusiaceae," and "animals, laboratory." Results. A total of 255 publications with plants this family were identified. From the initial 255 studies, a total of 21 studies were selected for the final analysis. Studies with genera Allanblackia, Clusia, Garcinia or Rheedia, and Hypericum showed significant anti-inflammatory activity. The findings include a decrease of total leukocytes, a number of neutrophils, total protein concentration, granuloma formation, and paw or ear edema formation. Other interesting findings included decreased of the MPO activity, and inflammatory mediators such as NF- κ B and iNOS expression, PGE2 and Il-1 β levels and a decrease in chronic inflammation. Conclusion. The data reported suggests the anti-inflammatory effect potential of Clusiaceae family in animal experiments.Entities:
Year: 2014 PMID: 24976853 PMCID: PMC4058220 DOI: 10.1155/2014/960258
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Flow diagram of the literature search.
Description of the anti-inflammatory aspects of the studies included in systematic review.
| References | Scientific name | Parts used | Animal | Dose | Route | Methods used | Action mechanism |
|---|---|---|---|---|---|---|---|
|
Trovato et al., 2001 [ |
| APME | Wistar rats | 100 mg/kg | i.p. | CIPE | Inhibition of PG |
|
Ozturk et al., 2002 [ |
| DAPE | Wistar rats | 25–60 mg/kg | i.p. | CIPE | Without mechanism |
|
Rabanal et al., 2005 [ |
| BME | Swiss mice | 0.25–1 mg/ear | t.a. | TPAIEE | Inhibition of AA metabolism |
|
Abdel-Salam 2005 [ |
| Commercial extract | Sprague-Dawley rats | 50–300 mg/kg | s.c. | CIPE | Inhibition of the liberation of HIS, 5-HT, KN |
|
Sánchez-Mateo et al., 2006 [ |
| BME | Swiss mice | 0.25–1 mg/ear | t.a. | TPAIEE | Inhibition of PLA2, COX, and LOX |
|
Nguemfo et al., 2007 [ |
| SBMCME | Wistar rats | 75–300 mg/kg | p.o. | CIPE; HSIPE; AAIPE; DIPE | Inhibition of AA metabolism |
|
Šavikin et al., 2007 [ |
| DAPE | Wistar rats | 25–200 mg/kg | p.o. | CIPE | Inhibition of NF- |
|
Frutuoso et al., 2007 [ |
| LAE | Swiss mice; Wistar rats | 10–100 mg/kg | p.o. | PILPS | Inhibition of neutrophil |
|
Ymele et al., 2013 [ |
| SBAE | Wistar rats | 100–400 mg/kg | p.o. | CIPE; HSIPE | Reduced liberation and action of His and 5-HT; |
|
Šavikin et al., 2007 [ |
| DAPE | Wistar rats | 25–200 mg/kg | p.o. | CIPE | Inhibition of NF- |
|
Panthong et al., 2007 [ |
| BEAE | Sprague-Dawley rats | 10–40 mg/kg | p.o. | EPPIEE; CIPE; AAIPE; GGICP | Inhibition of the liberation of His, PG, KN |
|
Castardo et al., 2008 [ |
| LHE | Swiss mice | 30–300 mg/kg | i.p. | CIPE; HSIPE; TPAIPE; BKIPE; AAIPE MPOAA; SPIPE | Inhibition of the activity of neuropeptides and PKC |
|
Galati et al., 2008 [ |
| APME | Wistar rats | 50; 70 mg/kg | i.p. | CIPE | Without mechanism |
|
Martins et al., 2008 [ |
| FPO | Wistar rats | 100 mg/kg | p.o. | CIPE | Without mechanism |
|
dos Reis et al., 2009 [ |
| FPE | Wistar rats | 0.5; 1.0 g/kg | p.o. | CITNBS; MPOAA; EMPGE2 | Inhibition COX-2 expression and production of PGE2 |
|
Zdunić et al., 2009 [ |
| FTOE | Wistar rats | 1.25 mL/Kg | p.o. | CIPE | Without mechanism |
|
Paterniti et al., 2010 [ |
| ME | Sprague-Dawley rats | 2 mg/kg | PIL; MPOAA; MVP; CE | Reduces the NF- | |
|
S |
| APOOE; APEE | Sprague-Dawley rats; Swiss mice | 50–400 mg/kg | p.o. | AcAICP | Without mechanism |
|
Otuki et al., 2011 [ |
| LHE; BHE; SHE | Swiss Webster mice | 0.01–1 mg/ear | t.a. | COIEE; MPOAA | Inflammatory signal transduction pathway not specified |
|
Ozturk et al., 2011 [ |
| LEE | Wistar rats | 30–300 mg/kg | p.o. | CIPE; PILPS; GGICP | Inhibition of the liberation of His, 5-HT, and BK |
|
Santos et al., 2011 [ |
| LHxE | Swiss mice | 50–200 mg/kg | i.p. | CIP; MTP; MTNF- | Inhibition of the neutrophil migration |
Abbreviations of parts used: APME: aerial parts methanol extract; APEE: aerial parts ethanolic extract; APOOE: aerial parts olive oil extract; BEAE: bark ethyl acetate extract; BHE: bark hydroalcoholic extract; BME: blossom methanol extract; DAPE: dried aerial parts extract; FPE: fruit peel extract; FPO: fruit pee oil; FTOE: flowering tops oil extracts; LAE: leaves aqueous extract; LHE: leaves hydroalcoholic extract; LEE: leaves ethanolic extract; LHxE: leaves hexanic extract; ME: methanolic extract; SBAE: stem bark aqueous extract; SBMCME: stem barks methylene chloride/methanol extract; SHE: seeds hydroalcoholic extract.
Abbreviations of administration routes: i.p.: intraperitoneal; p.o.: oral administration; t.a.: topical administration.
Abbreviations of methods used: AAIPE: arachidonic acid-induced paw edema; AcAICP: acetic acid-induced increase in capillary permeability; BKIPE: bradykinin induced paw edema; CE: cytokines expression; CIP: carrageenan-induced pleurisy; CIPE: carrageenan-induced paw edema; CITNBS: colitis induced by 2,4,6-trinitrobenzenesulfonic acid; DIPE; dextran-induced paw edema; COIEE: croton oil-induced ear edema; EMPGE2: evaluation of mucosal PGE2; EPPIEE: ethyl phenylpropiolate induced ear edema; GGICP: granulomatous growth induced by cotton pellet; HSIPE: histamine and serotonin induced paw edema; MPOAA: myeloperoxidase activity assay; MTNF-α: measurement of tumor necrosis factor alpha; MTP: measurement of total protein; PEILPS: peritonitis induced by lipopolysaccharide; PIL: peritonitis induced by ligature; PILPS: pleurisy induced by LPS; SPIPE: substance P induced paw edema; TPAIPE: 12-O-tetradecanoylphorbol 13-acetate induced paw edema.
Abbreviations of action mechanism: AA: arachidonic acid; BK: bradykinin; COX: cyclooxygenase; His: histamine; iNOS: inducible nitric oxide synthase; KN: kinins; LOX: lipoxygenase; MVP: measurement of vascular permeability; NF-κB: nuclear factor kappa B; PKC: protein kinase C; PLA2: phospholipase A2; PG: prostaglandin, 5-HT: 5-hydroxytryptamine.